Company intelligence / Profile preview
Jiaxing AnDiCon Biotech
Jiaxing, Zhejiang, Chinaandicon.cn ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
ADC189, a novel cap-dependent endonuclease inhibitor targeting the polymerase acidic protein of influenza viruses, has completed phase III trials in children in China and is at preregistration stage. The drug demonstrated rapid viral suppression with a single dose, high safety profile, no CNS side effects, and food-independent bioavailability. Other programs are in preclinical or IND stages targeting respiratory syncytial virus, mycoplasma infections, uterine fibroids, endometriosis, and COVID.
- Therapeutic areas
- Women's HealthInfectious Diseases
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Simcere Pharmaceutical Group Limited — exclusive commercialization rights for ADC189 in ChinaSimcere Pharmaceutical Group Limited — also an investor
Beyond the preview
Go deeper on Jiaxing AnDiCon Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jiaxing AnDiCon Biotech.